AR and prostate carcinoma: Enzalutamide is commonly used for advanced prostate cancer, particularly CRPC, but often encounters challenges like drug resistance, largely due to mutations in the AR, increased expression of splice variants like AR-V7, and activation of alternative signaling pathways [5,32,33,34].